# Drug Repurposing Mechanism Tracings

This report traces biological mechanisms for validated drug repurposing predictions.

## Summary

- **Predictions analyzed:** 5
- **Direct mechanisms found:** 5
- **Pathway-based mechanisms:** 5

---

## 1. Dantrolene → Heart Failure

**Evidence:** RCT P=0.034, 66% reduction in VT episodes

### Drug Targets (12 genes)
Key targets: ACHE, 24715, RYR1, RYR2, 689560, 16153, CYP3A4, 21926, 54231, 20190

### Disease-Associated Genes (188 genes)

### Direct Mechanism ✓
**3 shared gene(s):** 24715, 20190, RYR1

### Shared Pathways (28 total)

**Disease-relevant pathways:**
- Parkinson disease (hsa05012)
- Adrenergic signaling in cardiomyocytes (hsa04261)
- Alzheimer disease (hsa05010)
- Calcium signaling pathway (hsa04020)
- Cardiac muscle contraction (hsa04260)

### Bridge Genes
Drug targets in disease-relevant pathways: RYR1, RYR2, CYP3A4, RYR3, ACHE

### Biological Hypothesis
> Dantrolene directly modulates 24715, 20190, RYR1, which are implicated in D006333 pathophysiology.

**Expected mechanism:** RYR2 inhibition prevents aberrant calcium release

---

## 2. Lovastatin → Multiple Myeloma

**Evidence:** RCT: improved OS/PFS

### Drug Targets (280 genes)
Key targets: DNTTIP2, NFIL3, DNMT1, PUS1, FEN1, HSPD1, CYP3A4, IFRD2, TCTA, TIMM9

### Disease-Associated Genes (488 genes)

### Direct Mechanism ✓
**33 shared gene(s):** PCNA, APOA1, PRKCD, DNMT1, HRAS, XBP1, MYC, ICAM1, RAD51, 382056

### Shared Pathways (252 total)

**Disease-relevant pathways:**
- p53 signaling pathway (hsa04115)
- Type II diabetes mellitus (hsa04930)
- JAK-STAT signaling pathway (hsa04630)
- Insulin signaling pathway (hsa04910)
- B cell receptor signaling (hsa04662)

### Bridge Genes
Drug targets in disease-relevant pathways: NFIL3, DNMT1, FEN1, HSPD1, CYP3A4

### Biological Hypothesis
> Lovastatin directly modulates PCNA, APOA1, PRKCD, which are implicated in D009101 pathophysiology.

**Expected mechanism:** HMG-CoA reductase inhibition affects cholesterol synthesis

---

## 3. Rituximab → Multiple Sclerosis

**Evidence:** WHO Essential Medicine 2023

### Drug Targets (5 genes)
Key targets: XIAP, 8378, ABCB1, MS4A1, TP53

### Disease-Associated Genes (272 genes)

### Direct Mechanism ✓
**1 shared gene(s):** ABCB1

### Shared Pathways (61 total)

**Disease-relevant pathways:**
- p53 signaling pathway (hsa04115)
- Parkinson disease (hsa05012)
- NF-kappa B signaling pathway (hsa04064)
- Apoptosis (hsa04210)
- Transcriptional misregulation in cancer (hsa05202)

### Bridge Genes
Drug targets in disease-relevant pathways: TP53, XIAP, MS4A1, ABCB1

### Biological Hypothesis
> Rituximab directly modulates ABCB1, which are implicated in D009103 pathophysiology.

**Expected mechanism:** CD20 B-cell depletion reduces neuroinflammation

---

## 4. Pitavastatin → Rheumatoid Arthritis

**Evidence:** Superior to MTX alone in trials

### Drug Targets (487 genes)
Key targets: C5, MLH1, FZD1, MNAT1, IFRD2, TIMM9, GDI1, COG2, BLCAP, MELK

### Disease-Associated Genes (984 genes)

### Direct Mechanism ✓
**42 shared gene(s):** CBFB, FAS, APOA1, PEBP1, HLA-B, MMP2, C5, ABCA7, MIF, FUT1

### Shared Pathways (301 total)

**Disease-relevant pathways:**
- p53 signaling pathway (hsa04115)
- Type II diabetes mellitus (hsa04930)
- JAK-STAT signaling pathway (hsa04630)
- Insulin signaling pathway (hsa04910)
- B cell receptor signaling (hsa04662)

### Bridge Genes
Drug targets in disease-relevant pathways: BUB1B, LYPLA1, MMP2, C5, MLH1

### Biological Hypothesis
> Pitavastatin directly modulates CBFB, FAS, APOA1, which are implicated in D001172 pathophysiology.

**Expected mechanism:** Anti-inflammatory via cholesterol pathway modulation

---

## 5. Empagliflozin → Parkinson's Disease

**Evidence:** HR 0.80 in Korean observational study

### Drug Targets (6 genes)
Key targets: 64522, SLC5A1, 246787, SLC5A2, DPP4, INS

### Disease-Associated Genes (718 genes)

### Direct Mechanism ✓
**1 shared gene(s):** INS

### Shared Pathways (36 total)

**Disease-relevant pathways:**
- Type II diabetes mellitus (hsa04930)
- Insulin signaling pathway (hsa04910)
- Type I diabetes mellitus (hsa04940)
- Alzheimer disease (hsa05010)
- PI3K-Akt signaling pathway (hsa04151)

### Bridge Genes
Drug targets in disease-relevant pathways: DPP4, INS, SLC5A1

### Biological Hypothesis
> Empagliflozin directly modulates INS, which are implicated in D010300 pathophysiology.

**Expected mechanism:** SGLT2 inhibition may have neuroprotective effects

---
